Latest hyperphosphatemia Stories
-- Conference Call and Webcast Today at 5:00 p.m. ET -- FREMONT, Calif., May 5, 2015 /PRNewswire/ -- Ardelyx, Inc.
LONDON, February 26, 2015 /PRNewswire/ -- Phosphate Therapeutics, today announces that recruitment of subjects into PEACH, the first pivotal trial of PT20 in subjects with
FREMONT, Calif., Feb. 2, 2015 /PRNewswire/ -- Ardelyx, Inc.
-- Data Published Online in the Journal of the American Society of Nephrology -- FREMONT, Calif., Nov. 17, 2014 /PRNewswire/ -- Ardelyx, Inc.
-- Primary endpoint was met for 50 mg twice daily dosing -- FREMONT, Calif., Oct. 1, 2014 /PRNewswire/ -- Ardelyx, Inc.
Nephrologists Seem More Confident That an Iron-Based Phosphate Binder Will Impact the Use of IV Iron vs.
Interest in GCS-100, Velcalcetide, ST-10, GSK-1278863A and Rayaldee Ranges from Moderate to High, According to Findings from Decision Resources Group BURLINGTON, Mass., July 10, 2014 /PRNewswire/
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage
Marketing Approval Triggers Milestone Payment to Keryx NEW YORK, Jan. 17, 2014 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.